The evolving treatment landscape of higher-risk MDS
DOI:
https://doi.org/10.58931/cht.2022.1317Abstract
Myelodysplastic neoplasms (MDS) are a group of clonal hematopoietic stem cell disorders characterized by ineffective hematopoiesis, cytopenia, and morphologic dysplasia. Most cases of MDS are de novo, and a minority are post cytotoxic therapy About 30% of the cases will eventually progress to acute myeloid leukemia (AML), with a higher incidence among the higher-risk MDS group. MDS is a rare disorder with an overall incidence of 3.7-4.8/100,000; the rate increases with age.
References
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–1719.
Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2016, National Cancer Institute. Based on November 2018 SEER data submission, posted to the SEER website, April 2019. https://seer.cancer.gov/archive/csr/1975_2016/
Zeidan AM, Shallis R, Wang R, Davidoff A, Ma X. Epidemiology of myelodysplastic syndromes: Why characterizing the beast is a prerequisite to taming it. Blood Rev. 2019;34:1-15. DOI: https://doi.org/10.1016/j.blre.2018.09.001
Valent P, Orazi A, Steensma D, et al. Proposed minimal diagnostic criteria for myelodysplastic syndromes (MDS) and potential pre-MDS conditions. Oncotarget. 2017 Jul 5;8(43):73483-73500. doi:10.18632/oncotarget.19008 DOI: https://doi.org/10.18632/oncotarget.19008
Greenberg P, Cox C, LeBeau M, et al. International Scoring System for evaluating prognosis in myelodysplastic syndromes. Blood. 1997;89:2079-2088. DOI: https://doi.org/10.1182/blood.V89.6.2079
Greenberg P, Tuechler H, Schanz J, et al. Revised international prognostic scoring system for myelodysplastic syndromes. Blood. 2012 Sep 20;120(12):2454-65. DOI: https://doi.org/10.1182/blood-2012-03-420489
Bernard E, Tuechler H, Greenberg PL, et al. Molecular international prognostic scoring system for myelodysplastic syndromes. Blood. 2021;138 (Suppl 1):61.
Cheson BD, Greenberg PL, Bennett JM, et al. Clinical application and proposal for modification of the International Working Group (IWG) response criteria in myelodysplasia. Blood. 2006 Jul 15;108(2):419-25. DOI: https://doi.org/10.1182/blood-2005-10-4149
Steensma DP. Myelodysplastic syndromes current treatment algorithm 2018. Blood Cancer J. 2018 May 24;8(5):47. DOI: https://doi.org/10.1038/s41408-018-0085-4
Malcovati L, Hellström-Lindberg E, Bowen D, Adès L, et al. Diagnosis and treatment of primary myelodysplastic syndromes in adults: recommendations from the European LeukemiaNet. Blood. 2013 Oct 24;122(17):2943-64. DOI: https://doi.org/10.1182/blood-2013-03-492884
Fenaux P, Mufti GJ, Hellstrom-Lindberg E, et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study. Lancet Oncol. 2009 Mar;10(3):223-32. DOI: https://doi.org/10.1016/S1470-2045(09)70003-8
Garcia-Manero G, McCloskey J, Griffiths EA, et al. Pharmacokinetic exposure equivalence and preliminary efficacy and safety from a randomized cross over phase 3 study (ASCERTAIN study) of an oral hypomethylating agent ASTX727 (cedazuridine/decitabine) compared to IV decitabine [ASH abstract 846]. Blood. 2019;134(Suppl 1):846. DOI: https://doi.org/10.1182/blood-2019-122980
Kantarjian H, O’Brien S, Cortes J, et al. Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome. Cancer. 2006 Mar 1;106(5):1090-8. DOI: https://doi.org/10.1002/cncr.21723
Knipp S, Hildebrand B, Kündgen A, et al. Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes. Cancer. 2007 Jul 15;110(2):345-52. DOI: https://doi.org/10.1002/cncr.22779
Montalban-Bravo G, Kanagal-Shamanna R, Sasaki K, et al. NPM1 mutations define a specific subgroup of MDS and MDS/MPN patients with favorable outcomes with intensive chemotherapy. Blood Adv. 2019;3(6):922–933. DOI: https://doi.org/10.1182/bloodadvances.2018026989
Khoury JD, Solary E, Abla O, et al. The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Myeloid and Histiocytic/Dendritic Neoplasms. Leukemia. 2022;36:1703–1719. DOI: https://doi.org/10.1038/s41375-022-01613-1
Nakamura R, Saber W, Martens M, et al. A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplantation to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Advanced Myelodysplastic Syndrome: Blood and Marrow Transplant Clinical Trials Network Study 1102. Blood. 2020;136(Suppl 1):75;19-21.
Lindsley R, Saber W, Mar B et al. Prognostic Mutations in Myelodysplastic Syndrome after Stem Cell Transplantation. N Engl J Med. 2017;376(6):536-547. DOI: https://doi.org/10.1056/NEJMoa1611604
Stomper J, Rotondo JC, Greve G, et al. Hypomethylating agents (HMA) for the treatment of acute myeloid leukemia and myelodysplastic syndromes: mechanisms of resistance and novel HMA-based therapies. Leukemia. 2021 Jul;35(7):1873-1889. DOI: https://doi.org/10.1038/s41375-021-01218-0
Garcia JS, Wei AH, Jacoby MA, et al. Molecular Responses Are Observed across Mutational Spectrum in Treatment-Naïve Higher-Risk Myelodysplastic Syndrome Patients Treated with Venetoclax Plus Azacitidine. Blood 2021;138(Suppl 1):241. DOI: https://doi.org/10.1182/blood-2021-145613
Zeidan AM, Garcia JS, Fenaux P, et al. Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naïve higher-risk myelodysplastic syndromes. J Clin Oncol. 2021;39(15 Suppl):TPS7054. DOI: https://doi.org/10.1200/JCO.2021.39.15_suppl.TPS7054
Feng D, Gip P, McKenna KM, Zhao F, Mata O, et al. Combination treatment with 5F9 and azacitidine enhances phagocytic elimination of acute myeloid leukemia. Blood. 2018;132(Suppl 1):2729. DOI: https://doi.org/10.1182/blood-2018-99-120170
Sallman DA, Al Malki M, Asch AS, et al. Tolerability and efficacy of the first-in-class anti-CD47 antibody magrolimab combined with azacitidine in MDS and AML patients: Phase Ib results. J Clin Oncol. 2020 May;38(15 Suppl):7507. DOI: https://doi.org/10.1200/JCO.2020.38.15_suppl.7507
Sekeres M, Girshova L, Doronin V, et al. Pevonedistat (PEV) + Azacitidine (AZA) Versus AZA Alone As First-Line Treatment for Patients with Higher-Risk Myelodysplastic Syndromes (MDS)/Chronic Myelomonocytic Leukemia (CMML) or Acute Myeloid Leukemia (AML) with 20-30% Marrow Blasts: The Randomized Phase 3 PANTHER Trial. Blood. 2021;138(Suppl 1):242. DOI: https://doi.org/10.1182/blood-2021-146154
Brunner AM, Esteve J, Porkka K, et al. Efficacy and Safety of Sabatolimab (MBG453) in Combination with Hypomethylating Agents (HMAs) in Patients (Pts) with Very High/High-Risk Myelodysplastic Syndrome (vHR/HR-MDS) and Acute Myeloid Leukemia (AML): Final Analysis from a Phase Ib Study. Blood. 2021;138 (Suppl 1):244. DOI: https://doi.org/10.1182/blood-2021-146039
Garcia-Manero G, Wei A, Porkka K et al. MDS-420: Sabatolimab Plus Hypomethylating Agents (HMAs) in Patients with High-/Very High-risk Myelodysplastic Syndrome (HR/vHR-MDS) and Newly Diagnosed Acute Myeloid Leukemia (ND-AML): Subgroup Analysis of a Phase 1 Study. Clin Lymphoma Myeloma Leuk. 2021;21(Suppl 1)S350. DOI: https://doi.org/10.1016/S2152-2650(21)01811-5
Peterlin P, Turlure P, Chevallier P, et al. CPX 351 As First Line Treatment in Higher Risk MDS, a Phase II Trial By the GFM. Blood. 2021;138(Suppl 1):243. DOI: https://doi.org/10.1182/blood-2021-145123
Prébet T, Gore SD, Esterni B, et al. Outcome of high-risk myelodysplastic syndrome after azacitidine treatment failure. J Clin Oncol. 2011 Aug 20;29(24):3322-7. DOI: https://doi.org/10.1200/JCO.2011.35.8135
Published
How to Cite
Issue
Section
License
Copyright (c) 2022 Canadian Hematology Today
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
